These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30779635)

  • 61. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
    Cavallari LH
    Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
    Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
    Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
    [No Abstract]   [Full Text] [Related]  

  • 64. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
    Kim JH; Tan DS; Chan MYY
    Pharmacogenomics J; 2021 Apr; 21(2):243-250. PubMed ID: 33462345
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Precision Antiplatelet Therapy for CYP2C19 Genotype Variants for Achieving Better Clinical Outcomes.
    Cha JJ; Lim DS
    JACC Cardiovasc Interv; 2021 Jul; 14(13):1500-1501. PubMed ID: 34238560
    [No Abstract]   [Full Text] [Related]  

  • 66. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
    Dong P; Yang X; Bian S
    Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacogenetics of Antiplatelet Therapy.
    Castrichini M; Luzum JA; Pereira N
    Annu Rev Pharmacol Toxicol; 2023 Jan; 63():211-229. PubMed ID: 35914768
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clopidogrel and Genotyping.
    Ford NF
    J Invasive Cardiol; 2015 Aug; 27(8):E173-4. PubMed ID: 26232022
    [No Abstract]   [Full Text] [Related]  

  • 69. Reply: Precision Antiplatelet Therapy for CYP2C19 Genotype Variants for Achieving Better Clinical Outcomes.
    Pereira NL; Rihal CS; Farkouh ME
    JACC Cardiovasc Interv; 2021 Jul; 14(13):1501. PubMed ID: 34238561
    [No Abstract]   [Full Text] [Related]  

  • 70. Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention.
    Cheng KK; San Andres C; Salam E; Han J; Lee JC
    Am J Cardiol; 2023 Sep; 202():218-222. PubMed ID: 37473671
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
    Zeb I; Krim N; Bella J
    Expert Rev Cardiovasc Ther; 2018 May; 16(5):369-377. PubMed ID: 29589775
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
    Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
    Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 74. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
    Mirzaev KB; Rytkin E; Ryzhikova KA; Grishina EA; Sozaeva ZA; Fedorinov DS; Konova OD; Giliarov MI; Belyakova GA; Andreev DA; Sychev DA
    Drug Metab Pers Ther; 2018 Sep; 33(3):109-118. PubMed ID: 30171809
    [No Abstract]   [Full Text] [Related]  

  • 75. CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
    Choi IJ; Koh YS; Park MW; Her SH; Choi YS; Park CS; Park HJ; Kim PJ; Chung WS; Kim HS; Shin JG; Seung KB; Chang K
    Medicine (Baltimore); 2016 Jun; 95(26):e4049. PubMed ID: 27368038
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The effect of
    Tan K; Lian Z; Shi Y; Wang X; Yu H; Li M; Tian J; Ge Y
    Per Med; 2019 Jul; 16(4):301-312. PubMed ID: 31322488
    [No Abstract]   [Full Text] [Related]  

  • 77. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
    Fragoulakis V; Bartsakoulia M; Díaz-Villamarín X; Chalikiopoulou K; Kehagia K; Ramos JGS; Martínez-González LJ; Gkotsi M; Katrali E; Skoufas E; Vozikis A; John A; Ali BR; Wordsworth S; Dávila-Fajardo CL; Katsila T; Patrinos GP; Mitropoulou C
    Pharmacogenomics J; 2019 Oct; 19(5):438-445. PubMed ID: 30647444
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome.
    Lodhi H; Bhat KG; Guleria VS; Pillai RKJ; Goel R; Sharma N; Sharma A; Sharma V
    Indian Heart J; 2024; 76(4):268-270. PubMed ID: 39009080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.